Ignition builds and maintains open resources for the research community, such as the Atlas of Proteomic Technologies, which benchmarks next-generation commercial proteomics platforms and helps guide scientists towards the most appropriate assay for their study.

Because we build the benchmarks ourselves, our guidance on platform choice, study design, and target prioritization is evidence-led. We work with academic teams, foundations, and biotechs to make the calls that de-risk what comes next.

A promising drug target or biomarker only matters if researchers, platforms, and funders move in the same direction. Ignition sits at this intersection - translating between them so a candidate becomes a fundable diagnostic or therapeutic program.